Robust Growth in the Geographic Atrophy Market Driven by Aging Population and Technological AdvancesPune, Sept. 20, 2024 ...

The following is a summary of “Frequency and Longitudinal Course of Behavioral and Neuropsychiatric Symptoms in Participants ...

Delays in treatment for the rare genetic condition could lead to progressive muscle weakness and irreversible loss in motor ...

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA). According to the company, additional data from its Phase 2 ARCHER ...

A large, retrospective analysis of patients with amyotrophic lateral sclerosis (ALS) and progressive muscular atrophy (PMA) indicates that a substantial proportion of PMA patients develop upper ...

This CHMP opinion was made despite broad support for pegcetacoplan from the European retina community and multiple dissenting votes by CHMP members who supported a path to approval.” “We have seen the ...

Apellis Pharmaceuticals, Inc. (APLS) announced on Friday that the Committee for Medicinal Products for Human Use or CHMP of the ...

Phase 3 SAGA trial has revealed that Gildeuretinol clinically, meaningfully and safely reduced geographic atrophy lesions ...

U.S. providers surveyed said that getting insurance approval is time-consuming and can delay treatment for newborns with ...

Referring to computer chips, Trump claims “we hardly make chips any more” due to policies like those embraced by the ...

Theodore Leng, MD, MS, sat down with David Hutton of Ophthalmology Times to discuss his presentation on Progression of Newly ...

A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), ...